|
1
|
Dasari S and Tchounwou PB: Cisplatin in
cancer therapy: Molecular mechanisms of action. Eur J Pharmacol.
740:364–378. 2014.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Razvi Y, Chan S, McFarlane T, McKenzie E,
Zaki P, DeAngelis C, Pidduck W, Bushehri A, Chow E and Jerzak KJ:
ASCO, NCCN, MASCC/ESMO: A comparison of antiemetic guidelines for
the treatment of chemotherapy-induced nausea and vomiting in adult
patients. Support Care Cancer. 27:87–95. 2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Bloechl-Daum B, Deuson RR, Mavros P,
Hansen M and Herrstedt J: Delayed nausea and vomiting continue to
reduce patients' quality of life after highly and moderately
emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol.
24:4472–4478. 2006.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Navari RM: Management of
chemotherapy-induced nausea and vomiting: Focus on newer agents and
new uses for older agents. Drugs. 73:249–262. 2013.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Coates A, Abraham S, Kaye SB, Sowerbutts
T, Frewin C, Fox RM and Tattersall MH: On the receiving end-patient
perception of the side-effects of cancer chemotherapy. Eur J Cancer
Clin Oncol. 19:203–208. 1983.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Hesketh PJ: Chemotherapy-induced nausea
and vomiting. N Engl J Med. 358:2482–2494. 2008.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Van Laar ES, Desai JM and Jatoi A:
Professional educational needs for chemotherapy-induced nausea and
vomiting (CINV): Multinational survey results from 2388 health care
providers. Support Care Cancer. 23:151–157. 2015.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Hesketh PJ, Kris MG, Basch E, Bohlke K,
Barbour SY, Clark-Snow RA, Danso MA, Dennis K, Dupuis LL, Dusetzina
SB, et al: Antiemetics: American society of clinical oncology
clinical practice guideline update. J Clin Oncol. 35:3240–3261.
2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Berger MJ, Ettinger DS, Aston J, Barbour
S, Bergsbaken J, Bierman PJ, Brandt D, Dolan DE, Ellis G, Kim EJ,
et al: NCCN guidelines insights: Antiemesis, version 2.2017. J Natl
Compr Canc Netw. 15:883–893. 2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Roila F, Molassiotis A, Herrstedt J, Aapro
M, Gralla RJ, Bruera E, Clark-Snow RA, Dupuis LL, Einhorn LH, Feyer
P, et al: 2016 MASCC and ESMO guideline update for the prevention
of chemotherapy- and radiotherapy-induced nausea and vomiting and
of nausea and vomiting in advanced cancer patients. Ann Oncol. 27
(Suppl 5):v119–v133. 2016.PubMed/NCBI View Article : Google Scholar
|
|
11
|
von der Maase H, Sengelov L, Roberts JT,
Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A and Arning
M: Long-term survival results of a randomized trial comparing
gemcitabine plus cisplatin, with methotrexate, vinblastine,
doxorubicin, plus cisplatin in patients with bladder cancer. J Clin
Oncol. 23:4602–4608. 2005.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Bellmunt J, von der Maase H, Mead GM,
Skoneczna I, De Santis M, Daugaard G, Boehle A, Chevreau C,
Paz-Ares L, Laufman LR, et al: Randomized phase III study comparing
paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in
patients with locally advanced or metastatic urothelial cancer
without prior systemic therapy: EORTC intergroup study 30987. J
Clin Oncol. 30:1107–1113. 2012.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Hussain SA, Stocken DD, Riley P, Palmer
DH, Peake DR, Geh JI, Spooner D and James ND: A phase I/II study of
gemcitabine and fractionated cisplatin in an outpatient setting
using a 21-day schedule in patients with advanced and metastatic
bladder cancer. Br J Cancer. 91:844–849. 2004.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Kim YR, Lee JL, You D, Jeong IG, Song C,
Hong B, Hong JH and Ahn H: Gemcitabine plus split-dose cisplatin
could be a promising alternative to gemcitabine plus carboplatin
for cisplatin-unfit patients with advanced urothelial carcinoma.
Cancer Chemother Pharmacol. 76:141–153. 2015.PubMed/NCBI View Article : Google Scholar
|
|
15
|
De Santis M, Bellmunt J, Mead G, Kerst JM,
Leahy M, Maroto P, Gil T, Marreaud S, Daugaard G, Skoneczna I, et
al: Randomized phase II/III trial assessing gemcitabine/carboplatin
and methotrexate/carboplatin/vinblastine in patients with advanced
urothelial cancer who are unfit for cisplatin-based chemotherapy:
EORTC study 30986. J Clin Oncol. 30:191–199. 2012.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Einstein DJ and Sonpavde G: Treatment
approaches for cisplatin-ineligible patients with invasive bladder
cancer. Curr Treat Options Oncol. 20(12)2019.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Cohen J: A power primer. Psychol Bull.
112:155–159. 1992.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Saito M, Aogi K, Sekine I, Yoshizawa H,
Yanagita Y, Sakai H, Inoue K, Kitagawa C, Ogura T and Mitsuhashi S:
Palonosetron plus dexamethasone versus granisetron plus
dexamethasone for prevention of nausea and vomiting during
chemotherapy: A double-blind, double-dummy, randomised, comparative
phase III trial. Lancet Oncol. 10:115–124. 2009.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Morales-Barrera R, Bellmunt J, Suárez C,
Valverde C, Guix M, Serrano C, Gallén M and Carles J: Cisplatin and
gemcitabine administered every two weeks in patients with locally
advanced or metastatic urothelial carcinoma and impaired renal
function. Eur J Cancer. 48:1816–1821. 2012.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Sakaeda T, Kadoyama K and Okuno Y: Adverse
event profiles of platinum agents: Data mining of the public
version of the FDA adverse event reporting system, AERS, and
reproducibility of clinical observations. Int J Med Sci. 8:487–491.
2011.PubMed/NCBI View Article : Google Scholar
|
|
22
|
de Vos FY and de Wit R: Choosing
chemotherapy in patients with advanced urothelial cell cancer who
are unfit to receive cisplatin-based chemotherapy. Ther Adv Med
Oncol. 2:381–388. 2010.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Dogliotti L, Carteni G, Siena S, Bertetto
O, Martoni A, Bono A, Amadori D, Onat H and Marini L: Gemcitabine
plus cisplatin versus gemcitabine plus carboplatin as first-line
chemotherapy in advanced transitional cell carcinoma of the
urothelium: Results of a randomized phase 2 trial. Eur Urol.
52:134–141. 2007.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Sekine I, Segawa Y, Kubota K and Saeki T:
Risk factors of chemotherapy-induced nausea and vomiting: Index for
personalized antiemetic prophylaxis. Cancer Sci. 104:711–717.
2013.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Mukoyama N, Yoshimi A, Goto A, Kotani H,
Ishikawa K, Miyazaki N, Miyazaki M, Yamada K, Kikkawa F, Hasegawa
Y, et al: An analysis of behavioral and genetic risk factors for
chemotherapy-induced nausea and vomiting in Japanese subjects. Biol
Pharm Bull. 39:1852–1858. 2016.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Ministry of Education, Culture Sports,
Science and Technology/Ministry of Health, Labor and Welfare: The
ethical guidelines for medical and health research involving human
subjects. https://www.mhlw.go.jp/content/000757566.pdf. Accessed
March 23, 2021. (In Japanese).
|
